Literature DB >> 12601529

Association of a polymorphism of the phospholipase D2 gene with the prevalence of colorectal cancer.

Yoshiji Yamada1, Nobuyuki Hamajima, Tomoyuki Kato, Hiroji Iwata, Yoshitaka Yamamura, Masayuki Shinoda, Motokazu Suyama, Tetsuya Mitsudomi, Kazuo Tajima, Suzuno Kusakabe, Hitoshi Yoshida, Yoshiko Banno, Yukihiro Akao, Masashi Tanaka, Yoshinori Nozawa.   

Abstract

Phospholipase D plays an important role in transmembrane signaling in a variety of cell types and its activity is increased in certain cancers, suggesting that it also contributes to tumorigenesis. A C-->T transition at nucleotide 1814 of the human phospholipase D(2) gene, which results in a Thr-->Ile substitution at amino acid 577, was noted in the GenBank database. The relationship of this polymorphism to the prevalence of cancer of the esophagus, stomach, colon-rectum, lung, and breast in Japanese was investigated in a case-control study. The genotype of the phospholipase D(2) gene was determined by the polymerase chain reaction with confronting two-pair primers. Multivariate logistic regression analysis with adjustment for age, gender, and smoking status revealed that the frequency of the T allele of the 1814C-->T polymorphism was significantly higher in individuals with colorectal cancer than in controls. A significant association of the polymorphism with the prevalence of colorectal cancer was found in analyses assuming either dominant (TT+CT vs. CC) or additive (CT vs. CC) effects of the T allele, but the T allele was not associated with the prevalence of esophageal, gastric, lung, or breast cancer. The activities of phospholipase D in cell lysates or membrane fractions did not differ between cells transfected with cDNAs encoding the Thr-577 or Ile-577 variants of phospholipase D(2). These results suggest that the phospholipase D(2) gene is a susceptibility locus for colorectal cancer in Japanese individuals, although a functional effect of the 1814C-->T (Thr577Ile) polymorphism was not detected.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12601529     DOI: 10.1007/s00109-002-0411-x

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  22 in total

1.  Competitive amplification and unspecific amplification in polymerase chain reaction with confronting two-pair primers.

Authors:  Nobuyuki Hamajima; Toshiko Saito; Keitaro Matsuo; Kazuo Tajima
Journal:  J Mol Diagn       Date:  2002-05       Impact factor: 5.568

2.  Overexpression of phospholipase D1 in human breast cancer tissues.

Authors:  D Y Noh; S J Ahn; R A Lee; I A Park; J H Kim; P G Suh; S H Ryu; K H Lee; J S Han
Journal:  Cancer Lett       Date:  2000-12-20       Impact factor: 8.679

3.  Germ-line mutations of the APC gene in 53 familial adenomatous polyposis patients.

Authors:  Y Miyoshi; H Ando; H Nagase; I Nishisho; A Horii; Y Miki; T Mori; J Utsunomiya; S Baba; G Petersen
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-15       Impact factor: 11.205

Review 4.  Phospholipase D.

Authors:  J H Exton
Journal:  Biochim Biophys Acta       Date:  1998-12-08

Review 5.  Phospholipase D: molecular and cell biology of a novel gene family.

Authors:  M Liscovitch; M Czarny; G Fiucci; X Tang
Journal:  Biochem J       Date:  2000-02-01       Impact factor: 3.857

6.  A neutral phospholipase D activity from rat brain synaptic plasma membranes. Identification and partial characterization.

Authors:  V Chalifa; H Möhn; M Liscovitch
Journal:  J Biol Chem       Date:  1990-10-15       Impact factor: 5.157

7.  Neoplastic transformation and tumorigenesis associated with overexpression of phospholipase D isozymes in cultured murine fibroblasts.

Authors:  D S Min; T K Kwon; W S Park; J S Chang; S K Park; B H Ahn; Z Y Ryoo; Y H Lee; Y S Lee; D J Rhie; S H Yoon; S J Hahn; M S Kim; Y H Jo
Journal:  Carcinogenesis       Date:  2001-10       Impact factor: 4.944

8.  Phospholipase D2, a distinct phospholipase D isoform with novel regulatory properties that provokes cytoskeletal reorganization.

Authors:  W C Colley; T C Sung; R Roll; J Jenco; S M Hammond; Y Altshuller; D Bar-Sagi; A J Morris; M A Frohman
Journal:  Curr Biol       Date:  1997-03-01       Impact factor: 10.834

9.  ADP-ribosylation factor, a small GTP-dependent regulatory protein, stimulates phospholipase D activity.

Authors:  H A Brown; S Gutowski; C R Moomaw; C Slaughter; P C Sternweis
Journal:  Cell       Date:  1993-12-17       Impact factor: 41.582

10.  Polymerase chain reaction with confronting two-pair primers for polymorphism genotyping.

Authors:  N Hamajima; T Saito; K Matsuo; K Kozaki; T Takahashi; K Tajima
Journal:  Jpn J Cancer Res       Date:  2000-09
View more
  37 in total

1.  Design, synthesis, and biological evaluation of halogenated N-(2-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)ethyl)benzamides: discovery of an isoform-selective small molecule phospholipase D2 inhibitor.

Authors:  Robert R Lavieri; Sarah A Scott; Paige E Selvy; Kwangho Kim; Satyawan Jadhav; Ryan D Morrison; J Scott Daniels; H Alex Brown; Craig W Lindsley
Journal:  J Med Chem       Date:  2010-09-23       Impact factor: 7.446

2.  The transcription factors Slug (SNAI2) and Snail (SNAI1) regulate phospholipase D (PLD) promoter in opposite ways towards cancer cell invasion.

Authors:  Ramya Ganesan; Elizabeth Mallets; Julian Gomez-Cambronero
Journal:  Mol Oncol       Date:  2015-12-19       Impact factor: 6.603

Review 3.  Phosphatidic acid signaling to mTOR: signals for the survival of human cancer cells.

Authors:  David A Foster
Journal:  Biochim Biophys Acta       Date:  2009-03-02

Review 4.  Phospholipase D: enzymology, functionality, and chemical modulation.

Authors:  Paige E Selvy; Robert R Lavieri; Craig W Lindsley; H Alex Brown
Journal:  Chem Rev       Date:  2011-09-22       Impact factor: 60.622

5.  Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part II. Identification of the 1,3,8-triazaspiro[4,5]decan-4-one privileged structure that engenders PLD2 selectivity.

Authors:  Robert Lavieri; Sarah A Scott; Jana A Lewis; Paige E Selvy; Michelle D Armstrong; H Alex Brown; Craig W Lindsley
Journal:  Bioorg Med Chem Lett       Date:  2009-03-06       Impact factor: 2.823

Review 6.  Targeting phospholipase D with small-molecule inhibitors as a potential therapeutic approach for cancer metastasis.

Authors:  Wenjuan Su; Qin Chen; Michael A Frohman
Journal:  Future Oncol       Date:  2009-11       Impact factor: 3.404

7.  Inhibition of phospholipaseD2 increases hypoxia-induced human colon cancer cell apoptosis through inactivating of the PI3K/AKT signaling pathway.

Authors:  Maoxi Liu; Zhongxue Fu; Xingye Wu; Kunli Du; Shouru Zhang; Li Zeng
Journal:  Tumour Biol       Date:  2015-11-27

8.  Positive feedback regulation between phospholipase D and Wnt signaling promotes Wnt-driven anchorage-independent growth of colorectal cancer cells.

Authors:  Dong Woo Kang; Do Sik Min
Journal:  PLoS One       Date:  2010-08-12       Impact factor: 3.240

9.  Development of dual PLD1/2 and PLD2 selective inhibitors from a common 1,3,8-Triazaspiro[4.5]decane Core: discovery of Ml298 and Ml299 that decrease invasive migration in U87-MG glioblastoma cells.

Authors:  Matthew C O'Reilly; Sarah A Scott; Kyle A Brown; Thomas H Oguin; Paul G Thomas; J Scott Daniels; Ryan Morrison; H Alex Brown; Craig W Lindsley
Journal:  J Med Chem       Date:  2013-03-13       Impact factor: 7.446

Review 10.  Phospholipase D in cell signaling: from a myriad of cell functions to cancer growth and metastasis.

Authors:  Julian Gomez-Cambronero
Journal:  J Biol Chem       Date:  2014-07-02       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.